Back to Search Start Over

Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program.

Authors :
Danchin N
Farnier M
Zeller M
Puymirat E
Cottin Y
Belle L
Lemesle G
Cayla G
Ohlmann P
Jacquemin L
Perret T
Angoulvant D
Albert F
Ferrières J
Schiele F
Simon T
Source :
Journal of clinical lipidology [J Clin Lipidol] 2020 May - Jun; Vol. 14 (3), pp. 352-360.e6. Date of Electronic Publication: 2020 Apr 08.
Publication Year :
2020

Abstract

Background: Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.<br />Objectives: The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.<br />Methods: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.<br />Results: Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, than non-FH patients. Before adjustment, their 5-year survival and event-free survival did not differ from non-FH patients. After adjustment, however, both mortality (hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.15-2.89; P = .011) and the combined endpoint of death, AMI, or stroke (HR 2.22, 95% CI: 1.51-3.26; P < .001) were higher in FH patients. The higher risk in FH patients was also present in patients receiving high-intensity lipid-lowering therapy at discharge: adjusted HR for mortality 2.29, 95% CI: 1.18 to 4.47, P = .015; HR for cardiovascular events 2.57, 95% CI: 1.48 to 4.48, P = .001. Concordant results were observed in propensity score-marched cohorts.<br />Conclusions: The risk of long-term mortality and cardiovascular events is twice as high in FH than in non-FH patients, when adjusted on baseline characteristics, even for those receiving high-intensity lipid-lowering therapy. Additional therapeutic measures are needed in these patients.<br /> (Copyright © 2020. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1933-2874
Volume :
14
Issue :
3
Database :
MEDLINE
Journal :
Journal of clinical lipidology
Publication Type :
Academic Journal
Accession number :
32527469
Full Text :
https://doi.org/10.1016/j.jacl.2020.03.008